Loading...

Carl Peck, MD, PhD

Title(s)Professor, Bioengineering
SchoolSchool of Pharmacy
AddressLocation Required
Varies CA 00000
Phone202-427-7660
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Farewell to our Wonderful Friend and Colleague, J. Richard (Dick) Crout (1929-2020). Clin Pharmacol Ther. 2020 Oct 28. PMID: 33111972.
      View in: PubMed   Mentions:
    2. Scientific considerations for global drug development. Sci Transl Med. 2020 Jul 29; 12(554). Wilson JL, Cheung KWK, Lin L, Green EAE, Porrás AI, Zou L, Mukanga D, Akpa PA, Darko DM, Yuan R, Ding S, Johnson WCN, Lee HA, Cooke E, Peck CC, Kern SE, Hartman D, Hayashi Y, Marks PW, Altman RB, Lumpkin MM, Giacomini KM, Blaschke TF. PMID: 32727913.
      View in: PubMed   Mentions:    Fields:    
    3. Sir Alasdair Breckenridge 1937-2019. A Celebratory Tribute. Clin Pharmacol Ther. 2020 07; 108(1):22-25. PMID: 32279311.
      View in: PubMed   Mentions:
    4. Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation. Br J Clin Pharmacol. 2019 09; 85(9):1874-1877. PMID: 31290181.
      View in: PubMed   Mentions:
    5. Bayesian Approach to Establish Bioequivalence: Why and How? Clin Pharmacol Ther. 2019 02; 105(2):301-303. PMID: 30666630.
      View in: PubMed   Mentions:
    6. Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics. Physiol Rep. 2018 03; 6(5). PMID: 29488355.
      View in: PubMed   Mentions:
    7. Farewell to Our Good Friend, Outstanding Mentor, and Colleague Darrell R. Abernethy (1949-2017). Clin Pharmacol Ther. 2018 04; 103(4):552-555. Schwartz JB, Woosley RL, Peck CC. PMID: 29435985.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Poor medication adherence in clinical trials: consequences and solutions. Nat Rev Drug Discov. 2017 03; 16(3):149-150. PMID: 28154411.
      View in: PubMed   Mentions:
    9. Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013. Drug Des Devel Ther. 2016; 10:4005-4016. PMID: 27994442.
      View in: PubMed   Mentions:
    10. Farewell to our Good Friend and Outstanding Colleague David Flockhart (1952-2015). Clin Pharmacol Ther. 2016 Feb; 99(2):139-42. PMID: 26800329.
      View in: PubMed   Mentions:
    11. Impact of the pharmaceutical sciences on health care: a reflection over the past 50 years. J Pharm Sci. 2012 Nov; 101(11):4075-99. PMID: 22911654.
      View in: PubMed   Mentions:
    12. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011; 51:45-73. PMID: 20854171.
      View in: PubMed   Mentions:
    13. Quantitative clinical pharmacology is transforming drug regulation. J Pharmacokinet Pharmacodyn. 2010 Dec; 37(6):617-28. PMID: 20978827.
      View in: PubMed   Mentions:
    14. A roadmap for biomarker qualification. Nat Biotechnol. 2010 May; 28(5):444-5. PMID: 20458313.
      View in: PubMed   Mentions:
    15. Recommended changes to oncology clinical trial design: revolution or evolution? Eur J Cancer. 2008 Jan; 44(1):8-11. PMID: 17981025.
      View in: PubMed   Mentions:
    16. "Getting the dose right": facts, a blueprint, and encouragements. Clin Pharmacol Ther. 2007 Jul; 82(1):12-4. PMID: 17571068.
      View in: PubMed   Mentions:
    17. Preventing postmarketing changes in recommended doses and marketing withdrawals. Ernst Schering Res Found Workshop. 2007; (59):209-16. PMID: 17117726.
      View in: PubMed   Mentions:
    18. Current issues relating to drug safety especially with regard to the use of biomarkers: a meeting report and progress update. Eur J Pharm Sci. 2007 Feb; 30(2):107-12. PMID: 17196378.
      View in: PubMed   Mentions:
    19. Simulation of correlated continuous and categorical variables using a single multivariate distribution. J Pharmacokinet Pharmacodyn. 2006 Dec; 33(6):773-94. PMID: 17053984.
      View in: PubMed   Mentions:
    20. Evidence of effectiveness: how much can we extrapolate from existing studies? AAPS J. 2005 Oct 05; 7(2):E467-74. PMID: 16353924.
      View in: PubMed   Mentions:
    21. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol. 2005 Mar; 45(3):246-56. PMID: 15703360.
      View in: PubMed   Mentions:
    22. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPS PharmSci. 2004 Feb 09; 6(1):E6. PMID: 15198507.
      View in: PubMed   Mentions:
    23. Randomized concentration-controlled trials: motivations, use, and limitations. Clin Pharmacol Ther. 2003 Sep; 74(3):203-14. PMID: 12966364.
      View in: PubMed   Mentions:
    24. Postmarketing drug dosage changes. Pharmacoepidemiol Drug Saf. 2003 Jul-Aug; 12(5):425-6. PMID: 12899120.
      View in: PubMed   Mentions:
    25. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Clin Pharmacol Ther. 2003 Jun; 73(6):481-90. PMID: 12811358.
      View in: PubMed   Mentions:
    26. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther. 2003 Apr; 73(4):348-65. PMID: 12709725.
      View in: PubMed   Mentions:
    27. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol Drug Saf. 2002 Sep; 11(6):439-46. PMID: 12426927.
      View in: PubMed   Mentions:
    28. Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin Pharmacol Ther. 2001 Jun; 69(6):387-99. PMID: 11406736.
      View in: PubMed   Mentions:
    29. Biological sex analysis in clinical research. J Womens Health Gend Based Med. 2000 Nov; 9(9):933-4. PMID: 11103088.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther. 2000 Nov; 68(5):568-77. PMID: 11103759.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    31. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res. 2000 Nov; 17(11):1335-44. PMID: 11205725.
      View in: PubMed   Mentions:
    32. A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep. Clin Pharmacol Ther. 2000 Aug; 68(2):175-88. PMID: 10976549.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    33. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. J Clin Pharmacol. 2000 Aug; 40(8):803-14. PMID: 10934664.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    34. Assessment and reporting of clinical pharmacology information in drug labeling. Clin Pharmacol Ther. 2000 Mar; 67(3):196-200. PMID: 10741621.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    35. Simulation of clinical trials. Annu Rev Pharmacol Toxicol. 2000; 40:209-34. PMID: 10836134.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    36. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Eur J Pharm Sci. 2000; 10(4):iv-xiv. PMID: 11023342.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    37. Dr Marcus M. Reidenberg, recipient of the 1999 Harry Gold Award. Clin Pharmacol Ther. 1999 Jul; 66(1):1. PMID: 10430102.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. Treatment of tobacco dependence: innovative regulatory approaches to reduce death and disease: preface. Food Drug Law J. 1998; 53 suppl:1-8. PMID: 10342978.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    39. Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep. Clin Pharmacol Ther. 1997 Oct; 62(4):444-52. PMID: 9357396.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    40. Drug development: improving the process. Food Drug Law J. 1997; 52(2):163-7. PMID: 10557553.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    41. The essential role of integrative biomedical sciences in protecting and contributing to the health and well-being of our nation. Physiologist. 1994 Jun; 37(3):79-86. PMID: 8073080.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    42. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Clin Pharmacol. 1994 Feb; 34(2):111-9. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH. PMID: 8163710.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimals
    43. Understanding consequences of concurrent therapies. JAMA. 1993 Mar 24-31; 269(12):1550-2. PMID: 8445821.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    44. Dog mastocytoma cells produce transforming growth factor beta 1. J Clin Invest. 1992 Jul; 90(1):35-41. PMID: 1634619.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    45. Adaptive control with feedback strategies for suramin dosing. Clin Pharmacol Ther. 1992 Jul; 52(1):11-23. PMID: 1623689.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    46. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Pharm Sci. 1992 Jun; 81(6):605-10. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH. PMID: 1355792.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    47. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Pharm Res. 1992 Jun; 9(6):826-33. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH. PMID: 1409369.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    48. Clinical pharmacology training at the Food & Drug Administration. J Clin Pharmacol. 1992 May; 32(5):400-6. PMID: 1587956.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    49. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther. 1992 Apr; 51(4):465-73. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH. PMID: 1563216.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimals
    50. The randomized concentration-controlled trial: an evaluation of its sample size efficiency. Control Clin Trials. 1991 Dec; 12(6):780-94. PMID: 1665119.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    51. Chronobiology. Suggestions for integrating it into drug development. Ann N Y Acad Sci. 1991; 618:563-71. PMID: 2006810.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimals
    52. FDA regulation of prescription drug advertising. JAMA. 1990 Nov 14; 264(18):2424-5. PMID: 2232001.
      View in: PubMed   Mentions:    Fields:    
    53. FDA's position on the clozaril patient management system. Hosp Community Psychiatry. 1990 Aug; 41(8):876-7. PMID: 2401475.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    54. Transcutaneous theophylline collection in preterm infants. Clin Pharmacol Ther. 1990 Apr; 47(4):427-34. PMID: 2328550.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    55. Methodological issues in AIDS clinical trials. Discussion. Design of clinical trials--approaches to clinical trials design. J Acquir Immune Defic Syndr (1988). 1990; 3 Suppl 2:S27-36 discussion S37-9. PMID: 2231299.
      View in: PubMed   Mentions:
    56. 'Vasoconstriction'--skin blanching--assay for glucocorticoids--a critique. Arch Dermatol. 1989 Nov; 125(11):1558-61. PMID: 2817920.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    57. Understanding comparisons of drug introductions between the United States and the United Kingdom. Clin Pharmacol Ther. 1989 Aug; 46(2):139-45. PMID: 2758723.
      View in: PubMed   Mentions: 1     Fields:    
    58. Bayesian regression analysis of non-steady-state phenytoin concentrations: evaluation of predictive performance. Ther Drug Monit. 1989; 11(4):455-62. PMID: 2741195.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    59. Clinical utility of a Bayesian dosing program for phenytoin. Ther Drug Monit. 1989; 11(3):285-94. PMID: 2728087.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    60. Clinical assessment of a two-compartment Bayesian forecasting method for lidocaine. Ther Drug Monit. 1988; 10(1):74-9. Beach CL, Farringer JA, Peck CC, Crawford MH, Ludden TM, Clementi WA. PMID: 3376185.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    61. Evaluation of a Bayesian regression-analysis computer program for predicting phenytoin concentration. Clin Pharm. 1986 Jul; 5(7):580-5. PMID: 3755661.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    62. Current status of clinical pharmacology training in the United States. Clin Pharmacol Ther. 1986 Apr; 39(4):451-8. PMID: 3956065.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    63. Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. J Pharm Sci. 1985 Feb; 74(2):171-4. PMID: 2985774.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    64. Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data. J Pharmacokinet Biopharm. 1984 Oct; 12(5):545-58. PMID: 6520748.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    65. The problem of choosing weights in nonlinear regression analysis of pharmacokinetic data. Drug Metab Rev. 1984; 15(1-2):133-48. PMID: 6745079.
      View in: PubMed   Mentions: 15     Fields:    
    66. Pharmacokinetics and pharmacodynamics of 1,25-dihydroxyvitamin D3 in the chick. Endocrinology. 1982 Sep; 111(3):939-46. Bikle DD, Peck CC, Holford NH, Zolock DT, Morrissey RL. PMID: 6896685.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    67. Normal pharmacokinetics of doxapramin in a patient with renal failure and hypothyroidism. Br J Clin Pharmacol. 1981 Mar; 11(3):305-7. PMID: 7213532.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    68. Improved computer-assisted digoxin therapy. A method using feedback of measured serum digoxin concentrations. Ann Intern Med. 1975 May; 82(5):619-27. PMID: 1137256.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    69. Determinants of the renal clearance of digoxin. Clin Pharmacol Ther. 1975 Apr; 17(4):385-94. PMID: 1122680.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    70. Differences in serum digoxin concentrations between outpatients and inpatients: an effect of compliance? Clin Pharmacol Ther. 1974 Mar; 15(3):239-46. PMID: 4593118.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    71. Computer-assisted digoxin therapy. N Engl J Med. 1973 Aug 30; 289(9):441-6. PMID: 4763409.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    Carl's Networks
    Concepts (245)
    Derived automatically from this person's publications.
    _
    Co-Authors (8)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _